

Efficacy of Gabapentin for the Treatment of Alcohol Use Alcohol Withdrawal Symptoms

JAMA Internal Medicine

180, 728

DOI: [10.1001/jamainternmed.2020.0249](https://doi.org/10.1001/jamainternmed.2020.0249)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Changed Primary Outcome Between Trial Registration and Publication. JAMA Internal Medicine, 2020, 180, 1550.	5.1	1
2	Retrospective Analysis of Gabapentin for Alcohol Withdrawal in the Hospital Setting: The Mayo Clinic Experience. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2020, 4, 542-549.	2.4	4
3	Alcohol Addiction, Gut Microbiota, and Alcoholism Treatment: A Review. International Journal of Molecular Sciences, 2020, 21, 6413.	4.1	71
4	Changed Primary Outcome Between Trial Registration and Publicationâ€”Reply. JAMA Internal Medicine, 2020, 180, 1551.	5.1	0
5	Safety of Gabapentin Prescribed for Any Indication in a Large Clinical Cohort of 571,718 US Veterans with and without Alcohol Use Disorder. Alcoholism: Clinical and Experimental Research, 2020, 44, 1807-1815.	2.4	15
6	Moderation of Prazosinâ€™s Efficacy by Alcohol Withdrawal Symptoms. American Journal of Psychiatry, 2021, 178, 447-458.	7.2	33
7	Prazosin for Alcohol Use Disorder. Journal of Clinical Psychiatry, 2021, 82, .	2.2	1
8	Les gabapentinoÃ“desÃ“: une revue de la littÃ©rature. Toxicologie Analytique Et Clinique, 2021, 33, 44-63.	0.1	0
9	New approved and emerging pharmacological approaches to alcohol use disorder: a review of clinical studies. Expert Opinion on Pharmacotherapy, 2021, 22, 1291-1303.	1.8	18
10	Gabapentin dependence and withdrawal requiring an 18-month taper in a patient with alcohol use disorder: a case report. Journal of Addictive Diseases, 2021, 39, 1-6.	1.3	3
11	Non-medical Use of Prescription Gabapentinoids (Gabapentin and Pregabalin) in Five European Countries. Frontiers in Psychiatry, 2021, 12, 676224.	2.6	10
12	Treatment of opioid and alcohol withdrawal in a cohort of emergency department patients. American Journal of Emergency Medicine, 2021, 43, 17-20.	1.6	5
13	Alcohol-Related Liver Disease: Basic Mechanisms and Clinical Perspectives. International Journal of Molecular Sciences, 2021, 22, 5170.	4.1	51
14	Modernizing Withdrawal Management Services. Canadian Journal of Addiction, 2021, 12, 33-38.	0.4	0
15	An open-label pilot study of pregabalin pharmacotherapy for alcohol use disorder. American Journal of Drug and Alcohol Abuse, 2021, 47, 467-475.	2.1	3
16	In communities that offer a needle exchange program, does IVD use increase?. Evidence-Based Practice, 2021, Publish Ahead of Print, .	0.0	0
17	Pilot randomized placeboâ€“controlled clinical trial of highâ€“dose gabapentin for alcohol use disorder. Alcoholism: Clinical and Experimental Research, 2021, 45, 1639-1652.	2.4	8
18	Substance Use Withdrawal and Detox Strategies That Work. Journal of Psychosocial Nursing and Mental Health Services, 2021, 59, 12-15.	0.6	0

#	ARTICLE	IF	CITATIONS
19	Effects of Gabapentin on Dorsal Anterior Cingulate Cortex GABA and Glutamate Levels and Their Associations With Abstinence in Alcohol Use Disorder: A Randomized Clinical Trial. <i>American Journal of Psychiatry</i> , 2021, 178, 829-837.	7.2	14
20	Insights Into Improving Clinical Outcomes Across Psychiatric Disorders and Medical Comorbidities. <i>American Journal of Psychiatry</i> , 2021, 178, 779-782.	7.2	0
21	Diagnosis and Management of Substance Use Disorders in Athletes. <i>Advances in Psychiatry and Behavioral Health</i> , 2021, 1, 135-143.	0.7	2
22	Gabapentin Reduces Alcohol Intake in Rats by Regulating NF- κ B Signaling Pathway Via PPAR γ . <i>Alcohol and Alcoholism</i> , 2022, 57, 234-241.	1.6	1
23	Association between preoperative administration of gabapentinoids and 30-day hospital readmission: A retrospective hospital registry study.. <i>Journal of Clinical Anesthesia</i> , 2021, 73, 110376.	1.6	7
24	The Kaiser Permanente Northern California Adult Alcohol Registry, an Electronic Health Records-Based Registry of Patients With Alcohol Problems: Development and Implementation. <i>JMIR Medical Informatics</i> , 2020, 8, e19081.	2.6	12
25	Gabapentin for Alcohol-Related Disorders. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	6
26	Implementation of Screening, Brief Intervention, and Referral to Treatment (SBIRT) Training in Large Cohorts of Second Year Medical Students. <i>Alcoholism Treatment Quarterly</i> , 2022, 40, 22-34.	0.8	0
28	Gabapentin for Post-Hospitalization Alcohol Relapse Prevention; Should Gabapentin Be Considered for FDA Approval in the Treatment of Alcohol Use Disorder?: A Case Presentation and Literature Review. <i>Cureus</i> , 2020, 12, e8931.	0.5	0
29	Management of alcohol use disorder in patients with cirrhosis in the setting of liver transplantation. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 45-59.	17.8	50
30	Care of the Alcoholic Patient. , 2020, , 1-18.		0
31	Medikamente zur Behandlung von AbhÄngigkeitserkrankungen und abhÄngigem Verhalten. , 2021, , 627-706.		0
32	Gabapentin for alcohol use disorder. <i>Canadian Family Physician</i> , 2021, 67, 269.	0.4	0
34	Top 2020 studies relevant to primary care: From the PEER team. <i>Canadian Family Physician</i> , 2021, 67, 255-259.	0.4	0
36	The Spectrum of Alcohol Use. <i>Medical Clinics of North America</i> , 2022, 106, 43-60.	2.5	10
37	Alcohol Use Disorder in Older Adults. <i>Clinics in Geriatric Medicine</i> , 2022, 38, 1-22.	2.6	11
38	Review of Evidence-Based Strategies to Treat Alcohol Use Disorder. <i>Journal of Psychosocial Nursing and Mental Health Services</i> , 2021, 59, 7-11.	0.6	3
39	Alcohol craving and withdrawal at treatment entry prospectively predict alcohol use outcomes during outpatient treatment. <i>Drug and Alcohol Dependence</i> , 2022, 231, 109253.	3.2	13

#	ARTICLE	IF	CITATIONS
40	Care of the Alcoholic Patient. , 2022, , 807-823.		0
41	Novel Pharmacological Approaches to the Treatment of Depression. <i>Life</i> , 2022, 12, 196.	2.4	22
42	Behavioral characterization of withdrawal following chronic voluntary ethanol consumption via intermittent two-bottle choice points to different susceptibility categories. <i>Alcoholism: Clinical and Experimental Research</i> , 2022, 46, 614-627.	2.4	10
43	Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder. <i>Drugs</i> , 2022, 82, 251-274.	10.9	56
45	Outcomes After Implementation of a Benzodiazepine-Sparing Alcohol Withdrawal Order Set in an Integrated Health Care System. <i>JAMA Network Open</i> , 2022, 5, e220158.	5.9	7
46	Management of Alcohol Withdrawal Syndrome in Patients with Alcoholic Liver Disease. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 1527-1534.	0.9	2
47	Review article: current and emerging therapies for the management of cirrhosis and its complications. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1099-1115.	3.7	20
48	Should we treat patients with chronic alcohol dependency by antiepileptics?. <i>Neurologie Pro Praxi</i> , 2021, 22, 284-288.	0.1	0
49	GSK3 ^β Activity in Reward Circuit Functioning and Addiction. <i>NeuroSci</i> , 2021, 2, 443-466.	1.2	1
50	Alcohol withdrawal symptoms predict corticostriatal dysfunction that is reversed by prazosin treatment in alcohol use disorder. <i>Addiction Biology</i> , 2022, 27, e13116.	2.6	16
51	Alcohol use disorder in community management of chronic liver diseases. <i>Hepatology</i> , 2023, 77, 1006-1021.	7.3	13
52	Management of Alcohol Use Disorder in Patients With Alcoholic Liver Disease. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 1514-1526.	0.9	4
53	Top 2020 studies relevant to primary care. <i>Canadian Family Physician</i> , 2021, 67, 255-259.	0.4	0
54	Gabapentin for alcohol use disorder. <i>Canadian Family Physician</i> , 2021, 67, 269-269.	0.4	4
55	La gabapentine pour les troubles liés à la consommation d'alcool. <i>Canadian Family Physician</i> , 2021, 67, e104-e105.	0.4	0
56	Principales études pertinentes aux soins primaires en 2020. <i>Canadian Family Physician</i> , 2021, 67, e94-e98.	0.4	0
57	Incidence and Progression of Alcohol-Associated Liver Disease After Medical Therapy for Alcohol Use Disorder. <i>JAMA Network Open</i> , 2022, 5, e2213014.	5.9	36
58	Natural History of Alcohol-Associated Liver Disease: Understanding the Changing Landscape of Pathophysiology and Patient Care. <i>Gastroenterology</i> , 2022, 163, 840-851.	1.3	7

#	ARTICLE	IF	CITATIONS
61	Survey of critical care practices for alcohol withdrawal syndrome in the intensive care unit. JACCP Journal of the American College of Clinical Pharmacy, 2022, 5, 950-958.	1.0	1
62	Substance Use in HIV Populations. , 2021, , 277-286.		0
63	Does gabapentin decrease alcohol use in patients with alcohol use disorder?. Evidence-Based Practice, 2022, 25, 16-17.	0.0	0
64	Helpful or Harmful? The Therapeutic Potential of Medications with Varying Degrees of Abuse Liability in the Treatment of Substance Use Disorders. Current Addiction Reports, 0, , .	3.4	1
65	The place of gabapentinoids in providing specialized care to patients with mental and behavioral disorders according to the principles of evidence-based medicine (literature review). Ukraini Kyi Visnyk Psykhonevrolohii, 2022, , 74-80.	0.2	0
66	Brain glutamate and sleep efficiency associations following a ketogenic diet intervention in individuals with Alcohol Use Disorder. , 2022, 5, 100092.		4
67	Cyclic nucleotide phosphodiesterases in alcohol use disorders: involving gut microbiota. International Journal of Neuropsychopharmacology, 0, , .	2.1	0
68	Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review. Frontiers in Pharmacology, 0, 13, .	3.5	9
69	Evidence-Based Practices for Co-occurring Addiction and Mental Illness. , 2022, , 331-349.		0
70	Alcohol Use Disorders and Neurological Illnesses. , 2022, , 1247-1272.		0
71	Alcohol Use. Annals of Internal Medicine, 2022, 175, ITC145-ITC160.	3.9	13
72	Symptoms-triggered approach versus fixed-scheduled approach of benzodiazepines for management of alcohol withdrawal syndrome: Non-randomized controlled trial. Alcohol, 2023, 106, 10-14.	1.7	1
73	Gabapentin as a drug with a broad potential. Presentation of its use in medical conditions beyond the official registration. Journal of Education, Health and Sport, 2022, 12, 127-132.	0.1	0
74	Gabapentin increases the abuse liability of alcohol alone and in combination with oxycodone in participants with co-occurring opioid and alcohol use disorder. Pharmacology Biochemistry and Behavior, 2022, 221, 173482.	2.9	3
75	Alcohol use disorder with comorbid anxiety disorder: a case report and focused literature review. Addiction Science & Clinical Practice, 2022, 17, .	2.6	2
76	Effectiveness of a pharmacist-delivered primary care telemedicine intervention to increase access to pharmacotherapy and specialty treatment for alcohol use problems: Protocol for the alcohol telemedicine consult cluster-randomized pragmatic trial. Contemporary Clinical Trials, 2022, 123, 107004.	1.8	0
77	Application of gabapentinoids and novel compounds for the treatment of benzodiazepine dependence: the glutamatergic model. Molecular Biology Reports, 0, , .	2.3	2
78	The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de-risk trial programmes of novel agents. World Psychiatry, 2023, 22, 48-74.	10.4	40

#	ARTICLE	IF	CITATIONS
79	Types of addiction. , 2023, , 233-263.		0
80	Time to Treat Alcohol Use Disorder in the Emergency Department. <i>Annals of Emergency Medicine</i> , 2023, 81, 450-452.	0.6	2
81	Gabapentinoids: condemned without sufficient evidence?. <i>Lancet Regional Health - Europe</i> , The, 2023, 28, 100629.	5.6	0
82	Integrative Analysis of Proteome-wide Association Studies and Functional Enrichment Analysis to Identify Genes and Chemicals Associated with Alcohol Dependence. <i>Journal of Addiction Medicine</i> , 2023, 17, 319-325.	2.6	0
83	A randomized controlled clinical trial of prazosin for alcohol use disorder in active duty soldiers: Predictive effects of elevated cardiovascular parameters. <i>Alcoholism: Clinical and Experimental Research</i> , 2023, 47, 348-360.	2.4	2
84	Current evidence and clinical utility of phenobarbital for alcohol withdrawal syndrome. <i>European Journal of Internal Medicine</i> , 2023, 112, 52-61.	2.2	0
85	Emergency Department Management of Patients With Alcohol Intoxication, Alcohol Withdrawal, and Alcohol Use Disorder: A White Paper Prepared for the American Academy of Emergency Medicine. <i>Journal of Emergency Medicine</i> , 2023, 64, 517-540.	0.7	7
86	Pharmacotherapy options for alcohol use disorder in patients with alcohol-associated liver disease: a brief guide for clinicians. <i>Clinical Liver Disease</i> , 2023, 21, 125-129.	2.1	1
87	ERAS Protocol Options for Perioperative Pain Management of Substance Use Disorder in the Ambulatory Surgical Setting. <i>Current Pain and Headache Reports</i> , 2023, 27, 65-79.	2.9	3
88	Management of alcohol use disorder in patients with chronic liver disease. <i>Hepatology Communications</i> , 2023, 7, .	4.3	5
89	Acute and Chronic Ethanol Effects during Adolescence on Neuroimmune Responses: Consequences and Potential Pharmacologic Interventions. <i>Cells</i> , 2023, 12, 1423.	4.1	2
90	Medications for treating alcohol use disorder: A narrative review. <i>Alcoholism: Clinical and Experimental Research</i> , 2023, 47, 1224-1237.	2.4	1
91	Pharmacologic Management of Cancer-Related Pain in Pregnant Patients. <i>Drugs</i> , 2023, 83, 1067-1076.	10.9	0
92	Pharmacological Treatment of Substance Use Disorders. , 2023, , 1-28.		0
93	Novel paradigms for the gut-brain axis during alcohol withdrawal, withdrawal-associated depression, and craving in patients with alcohol use disorder. <i>Frontiers in Psychiatry</i> , 0, 14, .	2.6	1
94	Overview of Alcohol Use Disorder. <i>American Journal of Psychiatry</i> , 2023, 180, 565-572.	7.2	3
95	Toxidrome of an Easily Obtainable Nootropic. <i>Journal of Clinical Psychopharmacology</i> , 2023, 43, 507-510.	1.4	2
96	Treatment of severe tardive dyskinesia with concurrent administration of olanzapine, clonazepam, baclofen, and gabapentin: a case report. <i>Journal of International Medical Research</i> , 2023, 51, .	1.0	1

#	ARTICLE	IF	CITATIONS
97	GABAergic signaling in alcohol use disorder and withdrawal: pathological involvement and therapeutic potential. <i>Frontiers in Neural Circuits</i> , 0, 17, .	2.8	0
98	Approved, Promising, and Experimental Medications for Treatment of Alcohol Use Disorder. , 2023, , 261-288.		0
99	The Clinical Benefits of Non-abstinent Outcomes in Alcohol Use Disorder Treatment: Evidence from Clinical Trials and Treatment Implications. , 2023, , 341-364.		0
100	Medikamente zur Behandlung von AbhÄngigkeitserkrankungen und abhÄngigem Verhalten. , 2023, , 691-770.		0
101	Eliminating the benzos: A benzodiazepine-sparing approach to preventing and treating alcohol withdrawal syndrome. <i>Journal of Trauma and Acute Care Surgery</i> , 2024, 96, 394-399.	2.1	0
102	Mechanisms of SSRI Therapy and Discontinuation. <i>Current Topics in Behavioral Neurosciences</i> , 2023, , .	1.7	0
103	Concurrent opioid and alcohol withdrawal management. <i>Mental Health Clinician</i> , 2023, 13, 268-275.	1.0	0
104	Alcohol use disorder in the perioperative period: a summary and recommendations for anesthesiologists and pain physicians. <i>Regional Anesthesia and Pain Medicine</i> , 0, , rapm-2023-104354.	2.3	0
105	Bridging Neuroscience and Clinical Assessment in a Patient with Alcohol Use Disorder, Anxiety, and Trauma. <i>Journal of Psychiatric Practice</i> , 2024, 30, 62-67.	0.7	0
106	Addiction and Liver Disease: Exploring the Complex Relationship and Implications for Clinical Management. <i>Current Hepatology Reports</i> , 2024, 23, 110-122.	0.9	0
107	Astrocytic GABAergic Regulation in Alcohol Use and Major Depressive Disorders. <i>Cells</i> , 2024, 13, 318.	4.1	0
108	Quadruple pharmacotherapy for alcohol use disorder tolerable yet insufficient: a case report. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2024, 19, .	2.2	0
109	Acute Subjective Experiences of Intravenous Ketamine Therapy Among Medically Hospitalized Patients with Alcohol Use Disorder. , 0, , .		0
110	Current treatments of alcohol use disorder. <i>International Review of Neurobiology</i> , 2024, , 127-152.	2.0	0
111	Repurposing drugs for treatment of alcohol use disorder. <i>International Review of Neurobiology</i> , 2024, , 153-185.	2.0	0
113	Managing Alcohol Withdrawal Syndrome. <i>Annals of Emergency Medicine</i> , 2024, , .	0.6	0
114	A Narrative Review of Current and Emerging Trends in the Treatment of Alcohol Use Disorder. <i>Brain Sciences</i> , 2024, 14, 294.	2.3	0